CFO
GMAB icon

Callan Family Office’s Genmab GMAB Stock Holding History

Callan Family Office’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
55,033
-14
-0% -$372 0.03% 479
2026
Q1 		$1.48M Sell
55,047
-1,025
-2% -$30.7K 0.03% 445
2025
Q4 		$1.73M Buy
56,072
+21,055
+60% +$656K 0.04% 387
2025
Q3 		$1.07M Buy
35,017
+3,336
+11% +$81.3K 0.03% 364
2025
Q2 		$655K Buy
+31,681
New +$650K 0.02% 504
2025
Q1 		– Sell
-10,800
Closed -$225K – 590
2024
Q4 		$225K Buy
+10,800
New +$237K 0.01% 574

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Callan Family Office's GMAB Position: Q2 2026 in Review

Callan Family Office reduced its Genmab (GMAB) stake by 0.03% in Q2 2026, selling an estimated $372 and leaving 55,033 shares worth $1.51M. The position accounts for 0.03% of the portfolio, ranked #479.

Callan Family Office first reported a position in GMAB in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.73M in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Callan Family Office held 55,033 shares of Genmab worth $1.51M as of Q2 2026.
  • Callan Family Office sold 14 Genmab shares in Q2 2026, an estimated $372.
  • Genmab made up 0.03% of Callan Family Office's portfolio in Q2 2026, its #479 holding.
  • Callan Family Office first reported a position in Genmab in Q4 2024 and has held it in 6 quarters since.
  • Callan Family Office's Genmab position peaked at $1.73M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.